AIM AIM ImmunoTech

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).

The CEO Corner segment is now available . 

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.



For more information, please visit  and connect with the Company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
EN
25/04/2024

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated ...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort to begin escalated dosing soon OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (the “DURIPANC” study). See...

April 29, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DU...

April 25, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
NEOG Neogen Corporat...
MHLD Maiden Holdings... ... (+51)

InsiderInsights Weekly Report: April 20, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

NEOG NEOGEN CORPORATION
MHLD MAIDEN HOLDINGS LTD.
HNRG HALLADOR ENERGY CO.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
CRK COMSTOCK RESOURCES INC.
LULU LULULEMON ATHLETICA INC
RAIL FREIGHTCAR AMERICA INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
GLQ CLOUGH GLOBAL EQUITY FUND
WDFC WD-40 COMPANY
AINC ASHFORD
BRT BRT APARTMENTS
ISDR ISSUER DIRECT CORP.
LOVE LOVESAC
CWEN CLEARWAY ENERGY INC. CLASS C
ORGO ORGANOGENESIS HOLDINGS (A)
HROW HARROW HEALTH INC.
LEGH LEGACY HOUSING CORP
REEMF RARE ELEMENT RESOURCES
AIM AIM IMMUNOTECH
DCTH DELCATH SYSTEMS
HGBL HERITAGE GLOBAL
NKTX NKARTA
EGLE EAGLE BULK SHIPPING
SOWG SOW GOOD INC.
PHX PANHANDLE OIL AND GAS INC
SMMT SUMMIT THERAPEUTICS INC
AUID IPSIDY INC.
FSBC FIVE STAR BANCORP
DERM JOURNEY MEDICAL CORP
LEE LEE ENTERPRISES INC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
FTHY FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
TCBX THIRD COAST BANCSHARES INC
ASLE AERSALE CORP
AIKI AIKIDO PHARMA INC.
BUKS BUTLER NATIONAL CORP
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMAI NUVEEN MULTI-ASSET INCOME FUND
ACRV ACRIVON THERAPEUTICS INC
LSXMA LIBERTY SIRIUSXM GROUP
TISI TEAM INC.
CBSTF CANNABIST CO HOLDINGS INC.
TSVT 2SEVENTY BIO INC
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
INTZ INTRUSION INC
PROP PRAIRIE OPERATING CO.
LGVN LONGEVERON INC
OCX ONCOCYTE CORPORATION
04/21/24 April 21, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need. The CEO Corner segment is now available .  About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to tr...

April 18, 2024 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Off...

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Dr. Lapp has played a key role in AIM’s long-standing AMP-511 Expanded Access Program for the treatment of ME/CFS and Long COVID, having founded one of the clinical trial’...

April 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch